Free Trial
NASDAQ:OCUL

Ocular Therapeutix Q4 2023 Earnings Report

Ocular Therapeutix logo
$11.06 +0.02 (+0.18%)
Closing price 10/2/2025 04:00 PM Eastern
Extended Trading
$11.32 +0.26 (+2.35%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocular Therapeutix EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.28
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Ocular Therapeutix Revenue Results

Actual Revenue
$14.80 million
Expected Revenue
$15.31 million
Beat/Miss
Missed by -$510.00 thousand
YoY Revenue Growth
N/A

Ocular Therapeutix Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 11, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Ocular Therapeutix's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ocular Therapeutix Earnings Headlines

Ocular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from Chardan Capital
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale
Ocular Therapeutix Announces $475M Stock Offering
See More Ocular Therapeutix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email.

About Ocular Therapeutix

Ocular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation following ophthalmic surgery. Ocular Therapeutix also markets ReSure® Sealant, a synthetic polyethylene glycol-based hydrogel approved to seal corneal incisions and reduce postoperative fluid egress. These products exemplify the company’s strategy of combining novel delivery systems with established drug compounds to enhance safety and efficacy.

In addition to its marketed therapies, Ocular Therapeutix maintains a pipeline of investigational candidates targeting conditions such as glaucoma and dry eye disease. Key programs include OTX-TKI, a tyrosine kinase inhibitor insert under development for glaucoma, and OTX-DED, an insert incorporating low-dose dexamethasone for chronic dry eye. The company leverages partnerships and licensing agreements to expand its technology platform and advance clinical programs.

Led by Chief Executive Officer Antony Mattessich, Ocular Therapeutix operates manufacturing and research facilities in the United States and collaborates with contractors and distributors to support commercialization. The company’s management team combines expertise in ophthalmology, drug delivery, and regulatory affairs to guide product approvals and market access strategies within the U.S. and select international markets.

View Ocular Therapeutix Profile

More Earnings Resources from MarketBeat